Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-blinded, Multiple-dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC9204-1706 in Subjects Being Overweight or With Obesity

Next Previous
Trial Profile

A Randomised, Double-blinded, Multiple-dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC9204-1706 in Subjects Being Overweight or With Obesity

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NN-9423 (Primary)
  • Indications Obesity
  • Focus Adverse reactions
  • Sponsors Novo Nordisk

Most Recent Events

  • 16 Dec 2022 sults assessing prevalence of arrhythmias in participants with overweight or obesity from two clinical studies: NCT03661879 and NCT03308721 published in the Journal of Clinical Pharmacology
  • 17 Oct 2019 Status changed from active, no longer recruiting to completed.
  • 09 Oct 2019 Planned End Date changed from 5 Sep 2019 to 12 Oct 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top